A Lifesaving Push: Why WHO Is Expanding Sickle Cell Treatment for Children

The health body announced the move during the Sixty-Eighth Session of the WHO Regional Committee for the Eastern Mediterranean, pointing out that thousands of infants born with the inherited blood disorder die every year due to late diagnosis and a lack of basic medical intervention.

Under the new plan, the World Health Organization is calling on national health authorities to integrate sickle cell diagnosis into routine newborn screening programmes. The initiative also focuses on improving the local availability of essential medicines, including hydroxyurea and penicillin, which drastically reduce life-threatening complications in young patients.

What Happened?

Sickle cell disease is a genetic blood disorder that causes red blood cells to deform into a sickle shape, blocking blood flow and leading to severe pain, organ damage, and stroke.

According to global health estimates, more than 300,000 babies are born with the condition each year, with over 75 percent of these births occurring in sub-Saharan Africa. In many lower-income regions, up to 90 percent of children born with sickle cell disease die before their fifth birthday if they do not receive early intervention.

The WHO initiative aims to address this survival gap by establishing standard treatment guidelines and supporting governments to procure affordable medicines. Health ministers participating in the regional meeting backed the framework, agreeing to establish dedicated national control plans.

Why Does It Matter?

For families across affected regions, access to basic sickle cell care remains severely limited by cost and inadequate healthcare infrastructure.

Simple interventions, such as daily prophylactic penicillin to prevent severe infections and early childhood vaccinations, can dramatically lower mortality rates. Hydroxyurea, an oral medication that reduces the frequency of painful crises and hospital admissions, remains largely inaccessible or prohibitively expensive for millions of patients.

By encouraging bulk purchasing mechanisms and local manufacturing, the WHO strategy seeks to drop the cost of these essential treatments. Public health experts note that early screening combined with cheap, accessible therapy can transform sickle cell from a fatal childhood illness into a manageable chronic condition.

What Is The Background?

Sickle cell disease has historically received disproportionately low funding and global attention compared to other major infectious diseases, despite its heavy burden on public health systems.

In recent years, regional bodies and patient advocacy groups have pushed for the condition to be designated as a public health priority. Previous pilot projects in several African nations demonstrated that routine heel-prick screening at birth, paired with parental education, successfully reduced under-five mortality among diagnosed infants by more than 80 percent.

The WHO's expanded initiative builds on these regional successes, attempting to scale up screening capacity from localized research clinics to standard national healthcare networks.

What Comes Next?

The WHO will work alongside global partners, equipment manufacturers, and national health ministries to rollout technical guidance for newborn screening tools over the coming months.

Focus will initially center on high-burden countries in Africa and the Middle East, where pilot procurement schemes for hydroxyurea are scheduled to begin next year. Health authorities will be expected to track baseline diagnosis figures and report progress at future regional committees.

Governments are also expected to update their national essential medicines lists to ensure sickle cell treatments are subsidized under universal health coverage frameworks.